Companies · Other Health Care

PROFUSA, Inc.

SOUTH SAN FRANCISCO · Other Health Care

Diligence memoA one-page analyst read on PROFUSA, Inc. — recommendation, valuation, rhythm, risks.
$60.3M
Total raised · real
4
Rounds
4.0×
Latest step-up
Top 8%
Sector rank · raised
Series C
Latest stage · inferred · Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

PROFUSA, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.99× the median modeled value of Series C Other Health Care companies in 2016–2018 (40 peers) — value vs value, same stage and era.
  • Within the normal band (99% of peer median) for its niche.
Dormant
  • Last raise 8.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

PROFUSA, Inc. is one of 5376 Other Health Care companies tracked from SOUTH SAN FRANCISCO. By capital raised it ranks among the largest (ahead of 93% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
46
Investors (latest)
2018-05-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BPre-Seed · 2011-07-01 Raised $500K (real) Modeled valuation $15M (est)$500K$15MPre-Seed2011Seed · 2011-10-14 Raised $1.2M (real) Modeled valuation $30M (est)$1.2M$30MSeed2011Seed · 2013-08-23 Raised $2.8M (real) Modeled valuation $68M (est)$2.8M$68MSeed2013Series A · 2015-06-18 Raised $11M (real) Modeled valuation $227M (est)$11M$227MSeries A2015Series C · 2018-05-15 Raised $45M (real) Modeled valuation $1.0B (est)$45M$1.0BSeries C2018+$1.2M+$2.8M+$11M+$45MCumulative $61M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$500K · 2011
Seed$1.2M · 2011
Seed extension$2.8M · 2013
Series A$11.3M · 2015
Series C$45.1M · 2018no Series B on file

Stages are modeled from round size (public records carry no series label). No record for: Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$1.0B
Base estimate est.
$163.8M
Conservative case
$2.7B
Upside case
$300.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $15.4M · 2011-07-012011Seed · modeled $29.7M · 2011-10-14Seed · modeled $68.4M · 2013-08-23Series A · modeled $227.2M · 2015-06-18Series C · modeled $1.0B · 2018-05-152018
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
8.1 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
21 mo
Avg between rounds
$8.8M/yr
Capital velocity
15.0 yr
On record since
2011
First round
5
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 25× above median
This company$60.3M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.0× of median
This company$45.1M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 47× above median
This company$1.0B
Sector median$22.1M

Raised more than 93% of sector peers (real $). Modeled value above 97% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #22 of 40.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Specialty Networks, LLC · Series C Raised $94.5M · modeled $2.2B (est)New MMI Holdings, Inc. · Series C Raised $80.7M · modeled $1.8B (est)BioMatrix Holdings, L.L.C. · Series C Raised $80.0M · modeled $1.8B (est)Sea Hunter Holdings, LLC · Series C Raised $76.3M · modeled $1.7B (est)Bind Benefits, Inc. · Series C Raised $70.0M · modeled $1.6B (est)Endotronix Inc · Series C Raised $116.1M · modeled $1.6B (est)Great Basin Scientific, Inc. · Series C Raised $124.3M · modeled $1.6B (est)TransMedics, Inc. · Series C Raised $249.0M · modeled $1.5B (est)Landmark Health, LLC · Series C Raised $90.8M · modeled $1.4B (est)Rapid Micro Biosystems, Inc. · Series C Raised $134.6M · modeled $1.4B (est)Mdp Acm Holdings, Llc · Series C Raised $60.0M · modeled $1.4B (est)ACON BioMatrix Investors I, L.L.C. · Series C Raised $57.5M · modeled $1.3B (est)PROFUSA, Inc. (this company) Raised $60.3M · modeled $1.0B (est)PROFUSA, Inc.
CompanyStageRaised · realValue · estvs peer med.
Specialty Networks, LLCSeries C$94.5M$2.2B2.08×
New MMI Holdings, Inc.Series C$80.7M$1.8B1.77×
BioMatrix Holdings, L.L.C.Series C$80.0M$1.8B1.76×
Sea Hunter Holdings, LLCSeries C$76.3M$1.7B1.68×
Bind Benefits, Inc.Series C$70.0M$1.6B1.54×
Endotronix IncSeries C$116.1M$1.6B1.52×
Great Basin Scientific, Inc.Series C$124.3M$1.6B1.49×
TransMedics, Inc.Series C$249.0M$1.5B1.40×
Landmark Health, LLCSeries C$90.8M$1.4B1.34×
Rapid Micro Biosystems, Inc.Series C$134.6M$1.4B1.32×
Mdp Acm Holdings, LlcSeries C$60.0M$1.4B1.32×
ACON BioMatrix Investors I, L.L.C.Series C$57.5M$1.3B1.26×
PROFUSA, Inc. this companySeries C$60.3M$1.0B0.99×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$500K2011-07-01$2.8M$15.4M85%
Seed$1.2M2011-10-14$6.0M$29.7M85%
Seed$2.8M2013-08-23$13.8M$68.4M85%
Series A$11.3M2015-06-18$51.2M$227.2M85%
Series C$45.1M2018-05-15$300.4M$1.0B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$500K2011-07-01
    • First recorded raise — entered as Pre-Seed.
  2. Seed$1.2M2011-10-14
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • Switched to Rule 06 (was Rule 504).
    • 17 investors on this round.
  3. Seed$2.8M2013-08-23
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 29 investors on this round.
  4. Series A$11.3M2015-06-18
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 32 investors on this round.
  5. Series C$45.1M2018-05-15
    • Raised again after 35 mo — slower than the ~14 mo sector norm.
    • Round 4.0× larger than the prior — scaling up.
    • 46 investors on this round.
Intelligence
2020 ~Q1
Modeled next raise · ~21mo cadence
$135.2M
Modeled next size est.range $87.9M$216.3M
4.0×
Last step-up
$8.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kristen Helton1 other2011-07
Qianye Karen Liu1 other2015-06
Ben Hwang2013-08
Bill McMillan2018-05
Joan Siu Braddi2018-05
Natalie Wisniewski2011-07
NG Siu Wai2018-05
Thomas Gutshall2011-10
William McMillan2011-07
William Siu Frist2018-05
Registry & provenance

PROFUSA, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1479362
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CSLC Ultimate Holdings, LLCOther Health CareSeries C$60.5M$656.0Msame sector · same stage
FC Investors XXI LLCOther Health CareSeries C$60.0M$1.4Bsame sector · same stage
Mdp Acm Holdings, LlcOther Health CareSeries C$60.0M$1.4Bsame sector · same stage
1286392 B.C. Ltd.Other Health CareSeries C$60.7M$1.2Bsame sector · same stage
Geneoscopy, Inc.Other Health CareSeries C$58.4M$925.9Msame sector · same stage
Afferent Pharmaceuticals, Inc.Other Health CareSeries C$58.1M$1.3Bsame sector · same stage
ACON BioMatrix Investors I, L.L.C.Other Health CareSeries C$57.5M$1.3Bsame sector · same stage
Research Imaging Company, LLCOther Health CareSeries C$57.5M$678.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Prolaio, Inc.Other Health CareSeries B$223.8M87%
Proxima, Inc.Other Health CareSeed$4.5M86%
ProSomnus, Inc.Other Health CareSeries A$64.4M84%
Protean Biodiagnostics Inc.Other Health CareSeries A$35.4M84%
Prosomnus Holdings Inc.Other Health CareSeries A$70.6M84%
Proterris Inc.Other Health CareSeed$49.6M83%
Proskriptive, Inc.Other Health CarePre-Seed$6.2M83%
Kinnos Inc.Other Health CareSeries A$39.1M83%
Frequently asked
How much funding has PROFUSA, Inc. raised?
PROFUSA, Inc. has raised approximately $60.3M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is PROFUSA, Inc.'s estimated valuation?
Provath's modeled valuation for PROFUSA, Inc. is approximately $1.0B (modeled range $163.8M–$2.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is PROFUSA, Inc. at?
PROFUSA, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Tue May 15.
What does PROFUSA, Inc. do and where is it based?
PROFUSA, Inc. operates in the Other Health Care sector, based in SOUTH SAN FRANCISCO.
Explore related

See where PROFUSA, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at PROFUSA, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.